United States medicinal chemicals and botanical products industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Medicinal Chemicals And Botanical Products Stocks in USA: Revenue Cohort 1

Name: Medicinal Chemicals And Botanical Products Stocks in USA: Revenue Cohort 1 comparison snapshot
Creator: Fliar BI Prism

A five-company medicinal chemicals and botanical products cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 05 October 2026Not investment adviceRanked by Prism readiness

Readiness leaderChromaDex · 46

Strongest available pathCharlie's Holdings · -11.9%

Widest latest marginCharlie's Holdings · 21.5%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1NAGE · Nasdaq

ChromaDex

A U.S.-listed issuer classified by the SEC in Medicinal Chemicals And Botanical Products

Founded 1999Irvine$212.1M market cap

View full Companies Radar profile

46Cautious

Snapshot price$2.68as of page date

Monthly-close return-56.7%five-year window

FY2025 revenue$0.13BNiagen Bioscience, Inc.

Net margin13.4%FY2025

P/E snapshot14.1xone ratio, not a verdict

Prism attention0.3%share across these five

Filing track recordRevenue, USD billions

+91.9%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 17.7%

52-week position1% through range

$2.61$7.95

News mentions1.1K

Community mentions0partial coverage

U.S.-scope patents201

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal64/100
Management stability90/100
Market position11/100
Capital-event signal47/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 3 M&A involvements, 2 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 6 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2AAWH · OTC

AWH

A U.S.-listed issuer classified by the SEC in Medicinal Chemicals And Botanical Products

Founded 2014Cambridge, Massachusetts$101.8M market cap

View full Companies Radar profile

45Cautious

Snapshot price$0.50as of page date

Monthly-close return-93.5%five-year window

FY2022 revenue$0.41BAscend Wellness Holdings, Inc.

Net margin-19.9%FY2022

Prism attention0.4%share across these five

Filing track recordRevenue, USD billions

+22.1%

FY2021–FY2022 · 2 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 22.1%

52-week position19% through range

$0.34$1.20

News mentions1.3K

Community mentions0partial coverage

U.S.-scope patents533

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal44/100
Management stability90/100
Market position12/100
Capital-event signal71/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 4 M&A involvements, 2 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 2 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3CBDY · OTC

Target

A U.S.-listed issuer classified by the SEC in Medicinal Chemicals And Botanical Products

Founded 1964Pleasant Prairie, Wisconsin$0.3M market cap

View full Companies Radar profile

41Cautious

Snapshot price$0.00as of page date

Monthly-close return-96.3%five-year window

FY2025 revenue$0.00BTarget Group Inc.

Net margin-35.0%FY2025

Prism attention99.2%share across these five

Filing track recordRevenue, USD billions

+12836.7%

FY2020–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 237.3%

52-week position50% through range

$0.00$0.00

News mentions354.0K

Community mentions0partial coverage

U.S.-scope patents5063

Prism InsightsWhat sits behind the readiness signal
Observed risk 25/100higher means more observed risk

Earnings signal29/100
Management stability55/100
Market position58/100
Capital-event signal66/100
Innovation pulse57/100

Management signal

Leadership churn is flagged elevated; 33 key-person events were recorded in the latest 360-day window.

Market activity

Available history contains 81 M&A involvements, 69 asset-acquisition events and 96 contract events.

Innovation activity

Prism records 325 lifetime product-launch events, 24 in the latest 360 days, and 211 company announcements in that window.

Recent risk watch

Recent available records contain 5 lawsuit, 0 regulatory and 2 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4MRMD · OTCQX

MariMed Inc

A U.S.-listed issuer classified by the SEC in Medicinal Chemicals And Botanical Products

Founded 2011Norwood, Massachusetts$26.6M market cap

View full Companies Radar profile

35Cautious

Snapshot price$0.07as of page date

Monthly-close return-91.1%five-year window

FY2025 revenue$0.16BMARIMED INC.

Net margin-9.1%FY2025

Prism attention0.1%share across these five

Filing track recordRevenue, USD billions

+31.6%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 7.1%

52-week position8% through range

$0.06$0.18

News mentions278

Community mentions4partial coverage

U.S.-scope patents0

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal55/100
Management stability90/100
Market position0/100
Capital-event signal10/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5CHUC · OTC

Charlie's Holdings

A U.S.-listed issuer classified by the SEC in Medicinal Chemicals And Botanical Products

Founded 2001Costa Mesa, California$46.8M market cap

View full Companies Radar profile

28Avoid

Snapshot price$0.17as of page date

Monthly-close return-11.9%five-year window

FY2025 revenue$0.02BCharlie's Holdings, Inc.

Net margin21.5%FY2025

Prism attention0.0%share across these five

Filing track recordRevenue, USD billions

-2.7%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -0.7%

52-week position13% through range

$0.14$0.37

News mentions14

Community mentions0partial coverage

U.S.-scope patents0

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal47/100
Management stability70/100
Market position0/100
Capital-event signal0/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Charlie's Holdings

-11.9%

ChromaDex

-56.7%

MariMed Inc

-91.1%

AWH

-93.5%

Target

-96.3%

Latest revenue

USD billions, official filing scope shown on each company card.

AWH

$0.41B

MariMed Inc

$0.16B

ChromaDex

$0.13B

Charlie's Holdings

$0.02B

Target

$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Charlie's Holdings

21.5%

ChromaDex

13.4%

MariMed Inc

-9.1%

AWH

-19.9%

Target

-35.0%

Prism news attention

Normalized share across these five names; attention is not quality.

Target

99.2%

AWH

0.4%

ChromaDex

0.3%

MariMed Inc

0.1%

Charlie's Holdings

0.0%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized medicinal chemicals and botanical products news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Target leads the conversation

It holds 99.2% of measured medicinal chemicals and botanical products news attention and also carries the basket's largest revenue base at $0.00B.

Price path

Charlie's Holdings leads the available price paths

Its monthly-close return is -11.9% for the five-year window. At the other end, Target is -96.3% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Charlie's Holdings has the widest latest margin

Its FY2025 net margin is 21.5%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

ChromaDex shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at 14.1x while its five-year window price return is -56.7%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · NAGE

ChromaDex

1,139available Prism news records

Prism top themes

Earnings & financial performance

Price action & investor response

Capital allocation & transactions

Leadership & governance

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-38.5%88 latest 12m vs 143 prior 12m

Machine-classified coverage tone

88.5% positive-5.7 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 9stock price 7earnings report 6financial report 5annual earnings 5quarterly financials 5bear market 4net income 4

Keyword tag occurrences in available Prism news records.

Coverage: 2010-03-01–2026-06-05 · trend and themes shown through 2026-06

Areas of research · AAWH

AWH

1,263available Prism news records

Prism top themes

Earnings & financial performance

Price action & investor response

Leadership & governance

Legal, arbitration & regulatory

Capital allocation & transactions

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-10.2%123 latest 12m vs 137 prior 12m

Machine-classified coverage tone

87.9% positive-2.3 pp vs preceding four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

quarterly financials 14financial report 13cannabis policy reform discussions 12low-carbon hydrogen 12solar hydrogen 12renewable h2 11electrolytic hydrogen 11earnings report 11

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-15–2026-07-23 · trend and themes shown through 2026-07

Areas of research · CBDY

Target

354,019available Prism news records

Prism top themes

Price action & investor response

4,769

Macro demand & rates

4,150

Earnings & financial performance

2,455

Capital allocation & transactions

1,033

Leadership & governance

1,010

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-25.1%38,938 latest 12m vs 52,013 prior 12m

Machine-classified coverage tone

70.1% positive+1.2 pp vs preceding four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 2,296stock indices 1,202black friday offers 1,120cyber monday discounts 1,117retail season deals 967christmas deals 940black friday deals 938market momentum 935

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-08-06 · trend and themes shown through 2026-08

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

NAGE

ChromaDex

through 2026-06-03

Earnings releases 19Company announcements 2Leadership changes 2

2026-06-03
Leadership changes
ChromaDex has appointed Carlos Lopez as its new Senior Vice President, General Counsel.
2025-03-04
Earnings releases
Full Year 2024: Total net sales of $99.6 million, ... Achieved net income of $8.6 million, ... Basic and diluted earnings per share was $0.11, ... Adjusted EBITDA was $8.5 million.
2025-02-25
Company announcements
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces that it will hold a conference call on Tuesday, March 4, 2025, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year 2024 financial results.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

AAWH

AWH

through 2026-04-29

Earnings releases 39Leadership changes 19Company announcements 3Asset acquisitions 1Business contracts 1

2026-04-29
Earnings releases
today announced that it will hold a conference call on Wednesday, May 13, 2026, at 5:00 p.m. ET following the release of its first quarter 2026 financial results.
2026-02-08
Company announcements
Ascend Wellness Holdings Inc. March 2, 2026 April 29, 2026 AS
2024-08-29
Leadership changes
John Hartmann will no longer serve as Chief Executive Officer, and Mark Cassebaum has been terminated as Chief Financial Officer, effective immediately.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

CBDY

Target

through 2026-06-03

Company announcements 512Leadership changes 145Earnings releases 139Lawsuits 44M&A 33

2026-06-03
M&A
has announced a memorandum of understanding (MOU) for the intention to acquire shares in a leading integrated circuit design enterprise ("Target Company") in the PRC.
2026-06-03
Leadership changes
Grant McGee has joined US retailer Target as its new EVP and chief legal and compliance officer.
2026-06-02
Earnings releases
During the first quarter of Fiscal 2026, which went up until May 2, Target posted some seemingly solid results, with its net sales rising by 6.7% year over year, totaling $25.4 billion.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

MRMD

MariMed Inc

through 2025-11-05

Earnings releases 14Company announcements 1Leadership changes 1

2025-11-05
Earnings releases
MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the third quarter ended September 30, 2025.
2024-08-07
Leadership changes
today announced the appointment of Mario Pinho to Chief Financial Officer (“CFO”), effective August 9, 2024.
2024-03-11
Company announcements
For example, ongoing global supply chain issues with construction equipment and supplies has cost multistate operator MariMed Inc. (CSE: MRMD) (OTCQX: MRMD) months in delays at various expansion projects in multiple states.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

CHUC

Charlie's Holdings

through 2025-04-16

M&A 1

2025-04-16
M&A
On April 17, 2025, Charlie's Holdings, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC), announcing that it had entered into and completed an asset purchase agreement with R.J. Reynolds Vapor Company, a subsidiary of British American Tobacco (BAT), on April 16.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Medicinal Chemicals And Botanical Products Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary medicinal chemicals and botanical products news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

botanical ingredients market

3 sources63.9% extraction confidence

2022 extracted base$164.10B

2032 extracted forecast$331.90B

Implied source CAGR7.3%

numerous health and wellness benefitscritical factorsindustry's future trajectory

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Medicinal Chemicals And Botanical Products news pulse

24,227available Prism news records

Latest 12m volume-25.1%8869 vs 11845 records

Positive classified tone73.0%+1.8 pp vs prior four quarters

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

26Q4

Available U.S.-primary Prism records matching botanical, chemical, medicinal, ingredient. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

chemical plant explosions and hazardous material leaks

2,753

ethnobotany and traditional medicinal plant research

1,797

industrial accident investigations and reports

1,630

regulatory compliance in chemical industries

1,601

global chemical market trends and analysis

1,478

environmental contamination incidents

1,426

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

chemical safety assessments 1,653osha chemical standards 1,187chemical pricing 910chemical accident 818plant explosion 809bulk chemical suppliers 576commodity chemical sourcing 551cosmetic regulation 508

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

numerous health and wellness benefits

3 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

chemical plant explosions and hazardous material leaks

2,753 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

2,115 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

synthetic products can be perfect substitutes for organic products

2,615 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

-25.1% news volume

The latest 12 months contain 8,869 matched records versus 11,845 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

73.0% positive · +1.8pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2833 (Medicinal Chemicals And Botanical Products), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 1–7. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Medicinal Chemicals And Botanical Products Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 05 October 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

ChromaDex leads the readiness ranking

Its Prism readiness score is 46/100, the highest in this five-company comparison.

Open ChromaDex in Companies Radar

Scale and margin leadership sit with AWH and Charlie's Holdings

AWH has the largest displayed latest revenue at $0.41B; Charlie's Holdings has the widest displayed latest margin at 21.5%.

Open AWH in Companies Radar Open Charlie's Holdings in Companies Radar

Comparisons

Strongest versus weakest available price path

Charlie's Holdings is -11.9% for its five-year window; Target is -96.3% for its five-year window.

Open Charlie's Holdings in Companies Radar Open Target in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $0.41B for AWH to $0.00B for Target. Entity and filing-period labels remain visible on the company cards.

Open AWH in Companies Radar Open Target in Companies Radar

Anomalies

Target has the widest attention-readiness rank gap

It ranks #1 by measured news attention (99.2%) and #3 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Target in Companies Radar

Target shows a price-operating divergence to inspect

Its displayed filing-revenue change is +12836.7% while its available monthly-close return is -96.3%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Target in Companies Radar

Explanations

Attention measures coverage volume, not quality

Target's 99.2% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Target in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open ChromaDex's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 46/100 score.

Open ChromaDex in Companies Radar

Stress-test the largest divergence before forming a view

Compare Target's profile with Charlie's Holdings's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Target in Companies Radar Open Charlie's Holdings in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.